IHH Healthcare Berhad Proposes Renewal of Share Buy-Back Authority: What Investors Need to Know

Overview of the Proposal

IHH Healthcare Berhad (“IHH” or “the Company”), one of Asia’s largest private healthcare providers, has issued a Statement to Shareholders regarding the Proposed Renewal of Authority for IHH to purchase its own shares of up to 10% of the prevailing total number of issued shares. This proposal is set to be tabled as Special Business at the Company’s Sixteenth Annual General Meeting (“AGM”) scheduled for Monday, 25 May 2026 at 2.00 p.m. at the KLGCC Convention Centre in Kuala Lumpur and virtually.

Key Points of the Share Buy-Back Proposal

• Buy-Back Limit: The authority, if renewed, will enable IHH to purchase up to 10% of its issued shares, representing up to 883,615,346 shares based on the latest figure of 8,836,153,463 issued shares as of 31 March 2026.
• Duration: The renewed authority will be effective until the next AGM, the expiry of the period within which the next AGM must be held, or until revoked or varied by shareholders.
• Mechanism and Compliance: Purchases will be executed on Bursa Malaysia Securities Berhad (“Bursa Securities”) and must comply with Section 127 of the Companies Act 2016, Bursa’s Main Market Listing Requirements, and any prevailing legal and regulatory requirements.
• Dealing with Purchased Shares: The Board of Directors may:
  • Cancel purchased shares
  • Retain them as treasury shares, which can be resold on Bursa, distributed as share dividends, used for employee share schemes, used as purchase consideration, or other purposes as prescribed by law
• Funding: The buy-back will be funded entirely from internally generated funds and/or external borrowings, provided such purchases are backed by an equivalent amount of retained profits (latest audited retained profits: RM785 million as at 31 December 2025).
• No Treasury Shares Held: As of the latest practicable date, IHH holds no treasury shares and has not transacted in its own shares in the past 12 months.
• Employee Share Scheme: An LTIP (Long Term Incentive Plan) was established on 27 January 2026, but no units have been granted yet.

Important Considerations for Shareholders

• Potential Advantages:
  • Flexibility in managing dividend policy and capital structure
  • Ability to buy shares when undervalued, potentially supporting the share price
  • Potential enhancement of Earnings Per Share (EPS) by reducing the number of shares
  • Provides shares for employee incentive plans or use as acquisition consideration
• Potential Disadvantages:
  • Reduction of financial resources and working capital, possibly foregoing other investment opportunities
  • Reduction in available retained profits for dividends, as buy-backs must be backed by retained profits
• Effects on Key Financial Metrics:
  • If all purchased shares are cancelled, total issued shares would reduce from 8.84 billion to 7.95 billion, increasing EPS and potentially Net Asset (NA) per share if the buy-back price is below NA per share
  • Working capital will decrease due to cash outflow; resale of treasury shares would reverse this effect
  • No impact on dividend policy other than the effect on available cash and profits
• Impact on Substantial Shareholders:
  • Share buy-back will increase proportional holdings of major shareholders, including MBK Healthcare, Mitsui & Co., Pulau Memutik (Khazanah), and EPF
  • MBK Healthcare’s direct interest could rise from 32.69% to 36.32% (if buy-back is executed in full and shares are cancelled)
  • This could trigger a mandatory takeover offer under Malaysian Rules on Take-Overs if any shareholder’s holding crosses 33% or increases by more than 2% within a six-month period; MBK Healthcare and PACs will apply for exemption if necessary
• Public Shareholding Spread:
  • Current public shareholding spread is 35.57%; post buy-back (if all shares bought from public and held as treasury shares), this could reduce to 28.41% (well above the minimum 20% required by Bursa Securities)
• Historical Share Price Data:
  • 12-month price range: RM6.52 (July 2025 low) to RM9.39 (March 2026 high)
  • Last traded price as at 31 March 2026: RM8.98
• Shareholder Action Required:
  • Shareholders are strongly encouraged to read the full statement and vote on the resolution at the upcoming AGM. The outcome of the vote and subsequent share buy-back activity may have a direct impact on the Company’s share price, EPS, and capital structure.
  • Shareholders unable to attend may appoint proxies or submit their votes electronically.

Potential Impact on Share Price and Market Perception

• Share Buy-Backs Are Typically Viewed Positively: They can signal management’s confidence in the intrinsic value of the company and may support or increase share price, especially if IHH shares are perceived as undervalued.
• EPS Enhancement: With fewer shares outstanding, reported EPS may rise, which could be viewed favourably by analysts and institutional investors.
• Take-Over Implications: Any movement in substantial shareholders’ stakes near the 33% threshold could trigger mandatory general offers or require exemptions, which may add to share price volatility.
• Liquidity Considerations: Reducing the float could impact liquidity, but the public spread remains well above regulatory minimums.
• Market Timing: The Board’s intention to buy back shares only when they are “grossly below intrinsic value” hints at a value-driven approach, which could provide downside support to the stock.

Conclusion and Recommendation

The Board of Directors recommends shareholders vote in favour of the Proposed Renewal of Share Buy-Back Authority, citing its potential to enhance value for existing shareholders, provide flexibility for capital management, and support the Company’s overall strategic direction. The resolution will be tabled as Special Business at the Sixteenth AGM. Investors should be alert to the possibility of share price movements around the announcement, voting, and any subsequent buy-back activity.

For further information, shareholders are advised to review Appendix II of the Statement and refer to IHH’s Annual Report 2025 and the Company’s website.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell shares in IHH Healthcare Berhad. Investors should consult their own professional advisers regarding the implications of the proposed share buy-back and make investment decisions based on their own circumstances.

View IHH HEALTHCARE BERHAD Historical chart here